International Assets Investment Management LLC Purchases Shares of 11,760 CureVac (NASDAQ:CVAC)

International Assets Investment Management LLC purchased a new position in shares of CureVac (NASDAQ:CVAC) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 11,760 shares of the company’s stock, valued at approximately $35,000.

Other large investors also recently modified their holdings of the company. Private Advisor Group LLC bought a new stake in CureVac during the third quarter worth about $30,000. Bank of New York Mellon Corp bought a new stake in shares of CureVac during the 2nd quarter worth approximately $54,000. Signaturefd LLC boosted its holdings in shares of CureVac by 232.0% in the 2nd quarter. Signaturefd LLC now owns 22,043 shares of the company’s stock valued at $75,000 after buying an additional 15,403 shares during the last quarter. Green Alpha Advisors LLC grew its stake in shares of CureVac by 41.3% in the third quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company’s stock valued at $80,000 after buying an additional 7,979 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in CureVac during the second quarter worth $108,000. 17.26% of the stock is currently owned by institutional investors and hedge funds.

CureVac Stock Up 0.4 %

CVAC stock opened at $2.84 on Friday. CureVac has a 1-year low of $2.21 and a 1-year high of $6.30. The business’s 50 day simple moving average is $2.95 and its 200 day simple moving average is $3.25. The company has a current ratio of 2.29, a quick ratio of 2.28 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $635.82 million, a PE ratio of -2.12, a PEG ratio of 1.92 and a beta of 2.61.

CureVac (NASDAQ:CVAC) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The company had revenue of $15.55 million during the quarter, compared to analyst estimates of $10.07 million. CureVac had a negative net margin of 422.66% and a negative return on equity of 57.18%. As a group, research analysts anticipate that CureVac will post 0.05 EPS for the current year.

Analysts Set New Price Targets

Separately, JMP Securities reissued a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research report on Monday, September 16th.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.